Vaughan Nelson Investment Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.44M | Buy |
59,620
+950
| +2% | +$24.9K | 0.01% | 173 |
|
|
2026
Q1 | $1.65M | Hold |
58,670
| – | – | 0.02% | 165 |
|
|
2025
Q4 | $1.46M | Sell |
58,670
-30,000
| -34% | -$757K | 0.01% | 169 |
|
|
2025
Q3 | $2.26M | Hold |
88,670
| – | – | 0.02% | 161 |
|
|
2025
Q2 | $2.15M | Hold |
88,670
| – | – | 0.02% | 155 |
|
|
2025
Q1 | $2.25M | Hold |
88,670
| – | – | 0.02% | 161 |
|
|
2024
Q4 | $2.35M | Hold |
88,670
| – | – | 0.02% | 158 |
|
|
2024
Q3 | $2.57M | Buy |
88,670
+11,820
| +15% | +$345K | 0.02% | 155 |
|
|
2024
Q2 | $2.15M | Hold |
76,850
| – | – | 0.02% | 158 |
|
|
2024
Q1 | $2.13M | Hold |
76,850
| – | – | 0.02% | 161 |
|
|
2023
Q4 | $2.21M | Hold |
76,850
| – | – | 0.02% | 169 |
|
|
2023
Q3 | $2.55M | Buy |
76,850
+5,765
| +8% | +$204K | 0.03% | 172 |
|
|
2023
Q2 | $2.61M | Sell |
71,085
-6,105
| -8% | -$238K | 0.03% | 165 |
|
|
2023
Q1 | $3.15M | Sell |
77,190
-14,310
| -16% | -$618K | 0.04% | 154 |
|
|
2022
Q4 | $4.69M | Buy |
91,500
+2,375
| +3% | +$114K | 0.06% | 151 |
|
|
2022
Q3 | $3.9M | Hold |
89,125
| – | – | 0.06% | 143 |
|
|
2022
Q2 | $4.67M | Hold |
89,125
| – | – | 0.06% | 145 |
|
|
2022
Q1 | $4.61M | Buy |
89,125
+14,900
| +20% | +$773K | 0.05% | 147 |
|
|
2021
Q4 | $4.38M | Hold |
74,225
| – | – | 0.04% | 146 |
|
|
2021
Q3 | $3.19M | Buy |
74,225
+7,800
| +12% | +$346K | 0.03% | 152 |
|
|
2021
Q2 | $2.6M | Buy |
66,425
+5,600
| +9% | +$218K | 0.03% | 157 |
|
|
2021
Q1 | $2.2M | Buy |
60,825
+725
| +1% | +$25.7K | 0.02% | 150 |
|
|
2020
Q4 | $2.21M | Buy |
60,100
+22,946
| +62% | +$842K | 0.03% | 154 |
|
|
2020
Q3 | $1.29M | Hold |
37,154
| – | – | 0.02% | 162 |
|
|
2020
Q2 | $1.15M | Hold |
37,154
| – | – | 0.02% | 175 |
|
|
2020
Q1 | $1.15M | Hold |
37,154
| – | – | 0.02% | 179 |
|
|
2019
Q4 | $1.38M | Hold |
37,154
| – | – | 0.02% | 169 |
|
|
2019
Q3 | $1.27M | Hold |
37,154
| – | – | 0.02% | 167 |
|
|
2019
Q2 | $1.53M | Hold |
37,154
| – | – | 0.02% | 169 |
|
|
2019
Q1 | $1.5M | Hold |
37,154
| – | – | 0.02% | 170 |
|
|
2018
Q4 | $1.54M | Hold |
37,154
| – | – | 0.02% | 170 |
|
|
2018
Q3 | $1.55M | Hold |
37,154
| – | – | 0.02% | 176 |
|
|
2018
Q2 | $1.28M | Hold |
37,154
| – | – | 0.02% | 180 |
|
|
2018
Q1 | $1.25M | Hold |
37,154
| – | – | 0.02% | 177 |
|
|
2017
Q4 | $1.28M | Buy |
37,154
+14,546
| +64% | +$496K | 0.01% | 183 |
|
|
2017
Q3 | $766K | Buy |
+22,608
| New | +$727K | 0.01% | 196 |
|
Other funds holding PFE
Vaughan Nelson Investment Management's PFE Position: Q2 2026 in Review
Vaughan Nelson Investment Management increased its Pfizer (PFE) stake by 1.6% in Q2 2026, buying an estimated $24.9K and bringing the position to 59,620 shares worth $1.44M. The position accounts for 0.01% of the portfolio, ranked #173.
Vaughan Nelson Investment Management first reported a position in PFE in Q3 2017 and has held it in 36 quarters since. The position peaked at $4.69M in Q4 2022. 1,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Vaughan Nelson Investment Management held 59,620 shares of Pfizer worth $1.44M as of Q2 2026.
- Vaughan Nelson Investment Management bought 950 Pfizer shares in Q2 2026, an estimated $24.9K.
- Pfizer made up 0.01% of Vaughan Nelson Investment Management's portfolio in Q2 2026, its #173 holding.
- Vaughan Nelson Investment Management first reported a position in Pfizer in Q3 2017 and has held it in 36 quarters since.
- Vaughan Nelson Investment Management's Pfizer position peaked at $4.69M in Q4 2022.
- 1,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Vaughan Nelson Investment Management's 13F filing for Q2 2026, filed 16 Jul 2026.